The General Hospital Corporation, operating as Massachusetts General Hospital (MGH), received a $701,408 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The award aims to elucidate resistance mechanisms and enhance response to immune checkpoint blockade in central nervous system (CNS) metastases from breast cancer. The research involves profiling DNA, RNA, and immune cell behaviors in patient samples before, during, and after immunotherapy treatment, as well as studying novel combination therapies in mouse models of brain metastases. The overarching objective is to characterize mechanisms of resistance to immunotherapy in CNS metastases from breast cancer. The award period is from Jul 12, 2024 to Jun 30, 2029.
Generated 3/4/25, 6:37 AM